JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266207

Human SNRNP40 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SNRNP40 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 8 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human SNRNP40 knockout HEK-293T cell line (AB266207)
  • Sanger seq

Unknown

Sanger Sequencing - Human SNRNP40 knockout HEK-293T cell line (AB266207)

Allele-1 : 8 bp deletion in exon 1

Sanger Sequencing - Human SNRNP40 knockout HEK-293T cell line (AB266207)
  • Sanger seq

Unknown

Sanger Sequencing - Human SNRNP40 knockout HEK-293T cell line (AB266207)

Allele-2 : 1 bp insertion in exon 1.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 8 bp deletion in exon 1

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266207-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266207-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266207 Human SNRNP40 knockout HEK-293T cell line", "number":"AB266207-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266207-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266207-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266207 Human SNRNP40 knockout HEK-293T cell line", "number":"AB266207-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266207-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266207 Human SNRNP40 knockout HEK-293T cell line", "number":"AB266207-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266207-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266207 Human SNRNP40 knockout HEK-293T cell line", "number":"AB266207-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SNRNP40
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SNRNP40 also known as U5-40K or Splicing Factor 40 kDa is a component of the U5 small nuclear ribonucleoprotein complex. It has a mass of approximately 40 kDa. SNRNP40 is mainly expressed in the nucleoplasm of eukaryotic cells where it plays a critical role in RNA processing.
Biological function summary

SNRNP40 participates in the pre-mRNA splicing process as part of the spliceosome a large and dynamic ribonucleoprotein complex. The spliceosome facilitates the removal of introns from pre-mRNA transcripts. SNRNP40 as a part of this complex influences the conformational changes necessary for the accurate assembly and function of the spliceosome. Through this action SNRNP40 helps maintain genomic stability and proper gene expression.

Pathways

SNRNP40's role in the spliceosome places it within essential RNA processing pathways including the mRNA splicing pathway. It interacts with other proteins such as PRPF8 and EFTUD2 (also known as Snu114) which are key components of the U5 particle. These interactions illustrate how SNRNP40's activity is integral to the functioning of the spliceosomal machinery.

SNRNP40 has been connected to certain genetic conditions through its role in RNA splicing. Defects in the splicing process can result in splicing-related disorders such as retinitis pigmentosa although SNRNP40 itself is not directly implicated in this disease. However it shares functional associations with proteins like PRPF31 which is linked to such disorders. Additionally SNRNP40 may play a role in cancer development due to its involvement in mis-splicing events affecting tumor suppressor genes and oncogenes.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com